
    
      Each RA patients (n=47) with DAS>3.2 received low-dose IL-2+MTX+ Loxoprofen or placebo+MTX +
      Loxoprofen (active group: placebo group =1:1, 1 million units every other day subcutaneously
      (hrIL-2 1Ã—106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started)
      for 3 cycles. The end points were safety and clinical and immunologic response.
    
  